Triazolopyrazine Syk Inhibitors for Autoimmune Signal Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, allergic disorders, and certain types of cancer are inadequate due to the lack of effective inhibitors for Spleen Tyrosine Kinase (Syk), which plays a critical role in B-cell activation, mast cell degranulation, and osteoclast activity.
Innovation Solution
Development of novel compounds that act as Syk inhibitors, including substituted [1,2,4]triazolo[1,5-a]pyrazines, which can be used in pharmaceutical compositions to regulate Syk activity and modulate signal transduction pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune and inflammatory diseases are used, then existing therapeutic options are available, but the treatments are inadequate due to lack of effective Syk inhibitors
Solution Approach 1:
The patent segments the broad category of kinase inhibitors into specific Syk inhibitors with distinct molecular structures (Formula I compounds). This segmentation allows for targeted inhibition of Syk enzyme activity while potentially sparing other kinases, thereby improving treatment reliability for Syk-driven diseases without requiring broad-spectrum kinase inhibition.
Solution Approach 2:
The patent employs parameter changes by optimizing specific molecular parameters of the inhibitor compounds (substitution patterns, molecular weight, hydrophobicity) to achieve optimal Syk binding affinity and selectivity. This enables the development of effective Syk inhibitors where none previously existed, resolving the contradiction between treatment effectiveness and availability of specific inhibitors.
2Reliability
If Syk activity is inhibited to treat autoimmune diseases and inflammatory disorders, then therapeutic benefits are achieved, but the complexity of identifying effective inhibitors increases
Solution Approach 1:
The patent describes a series of compounds (Formula I) with varying substituents that all share the core [1,2,4]triazolo[1,5-a]pyrazine structure. This universal core structure provides a platform for developing multiple Syk inhibitors with different pharmacokinetic properties, allowing therapeutic benefits to be achieved while managing development complexity through a focused structural framework.
Solution Approach 2:
The patent systematically varies molecular parameters (substituents at different positions, molecular weight, lipophilicity) around the core structure to optimize Syk inhibition while maintaining drug-like properties. This parameter optimization approach enables the identification of effective inhibitors without requiring complete de novo design, thereby managing the complexity of inhibitor development.
3Adaptability or versatility
If novel compounds are developed as Syk inhibitors, then effective treatment options are created, but the manufacturing and development process becomes more complex
Solution Approach 1:
The patent segments the molecule into a core [1,2,4]triazolo[1,5-a]pyrazine structure and variable substituent groups. This segmentation allows the core structure to be synthesized once and then coupled with different substituents through standardized reactions, simplifying the manufacturing process while enabling the development of multiple effective inhibitors with tailored properties.
Solution Approach 2:
The patent establishes a universal core structure that can serve as a platform for multiple drug candidates. This core structure with its specific chemical properties enables consistent manufacturing processes across the compound series, while the variable substituents allow optimization for different disease indications and patient populations, thereby increasing availability without proportionally increasing manufacturing complexity.
Data Source
AI summary
The present invention provides compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk.